REG - Proteome Sciences - Trading Update and Notice of Results

Proteome SciencesAnnouncement

26/03/2021 07:00

RNS Number : 5663T
  
Proteome Sciences PLC
  
26 March 2021
  
 

 
 
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain. 
                                                                        26 March 2021
Proteome Sciences plc
("Proteome Sciences" or the "Company")
 
Trading Update and Notice of Results 
Following the Company's announcement on 25 January 2021 the Company has been progressing the year end audit and anticipates being able to announce the 2020 full year results on Thursday, 1 April 2021. The Directors of Proteome Sciences are pleased to announce that the Company now expects to report profit after tax materially higher than announced on 25 January.  This is primarily due to higher than expected royalty receipts from Thermo Scientific for the last quarter of 2020.  The annual results are still subject to finalisation of the audit and approval by the Board.
The Directors of Proteome Sciences look forward to updating shareholders on the Company's performance at the time of announcing the full results.  
For further information please contact:



Proteome Sciences plc 
 




Dr. Mariola Soehngen, Chief Executive Officer


Tel: +44 (0)20 7043 2116




Dr Ian Pike Chief Scientific Officer
 








Richard Dennis, Chief Commercial Officer
























Allenby Capital Limited (AIM Nominated Adviser & Broker)  




John Depasquale / Jeremy Porter 


Tel: +44 (0) 20 3328 5656



About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCFFFVIVEIEFIL